<html><body><h2>Case: 1192166</h2><h3> CDS Time: 2011-05-31</h3>
<patient name=1192166>
88.0 year old White_Non-Hispanic Female
<p><b>Lab & Note Entry Values:</b> <table>
<b><tr><td width="200">Lab</td><td width="200">Value</td><td width="200">Date</td></tr></b>
<tr><td width="200">Age</td><td width="200">88</td><td width="200">1970-1-1</td></tr>
<tr><td width="200">Calcium</td><td width="200">10</td><td width="200">1987-10-14</td></tr>
<tr><td width="200">Alkaline_phosphatase</td><td width="200">150</td><td width="200">1987-4-14</td></tr>
<tr><td width="200">Phosphorus</td><td width="200">4</td><td width="200">1987-4-14</td></tr>
<tr><td width="200">LDL_Cholesterol</td><td width="200">49</td><td width="200">1987-3-21</td></tr>
<tr><td width="200">Chloride</td><td width="200">102.0</td><td width="200">1987-10-14</td></tr>
<tr><td width="200">HDL_Cholesterol</td><td width="200">34</td><td width="200">1987-3-21</td></tr>
<tr><td width="200">Diastolic_BP</td><td width="200">60</td><td width="200">1988-3-21</td></tr>
<tr><td width="200">B 12</td><td width="200">493.0</td><td width="200">1986-1-11</td></tr>
<tr><td width="200">Weight</td><td width="200">165</td><td width="200">1987-12-30</td></tr>
<tr><td width="200">HbA1C</td><td width="200">8</td><td width="200">1987-10-14</td></tr>
<tr><td width="200">Triglycerides</td><td width="200">117</td><td width="200">1987-3-21</td></tr>
<tr><td width="200">Total_Cholesterol</td><td width="200">100</td><td width="200">1987-3-21</td></tr>
<tr><td width="200">SGOT</td><td width="200">17</td><td width="200">1987-4-14</td></tr>
<tr><td width="200">Systolic_BP</td><td width="200">116</td><td width="200">1988-3-21</td></tr>
<tr><td width="200">Total_Bilirubin</td><td width="200">0</td><td width="200">1987-4-14</td></tr>
<tr><td width="200">Height</td><td width="200">61</td><td width="200">1986-7-25</td></tr>
<tr><td width="200">Potassium</td><td width="200">5</td><td width="200">1987-10-14</td></tr>
<tr><td width="200">Cholesterol</td><td width="200">100</td><td width="200">1987-3-21</td></tr>
<tr><td width="200">BUN</td><td width="200">33</td><td width="200">1987-10-14</td></tr>
<tr><td width="200">HCT</td><td width="200">37</td><td width="200">1987-4-14</td></tr>
<tr><td width="200">HGB</td><td width="200">12</td><td width="200">1987-4-14</td></tr>
<tr><td width="200">Sodium</td><td width="200">140</td><td width="200">1987-10-14</td></tr>
<tr><td width="200">Albumen</td><td width="200">4</td><td width="200">1987-4-14</td></tr>
<tr><td width="200">Creatinine</td><td width="200">1.3</td><td width="200">1987-10-14</td></tr>
<tr><td width="200">Glycosylated_Hemoglobin</td><td width="200">8</td><td width="200">1987-10-14</td></tr>
<tr><td width="200">Pulse</td><td width="200">82</td><td width="200">1988-3-21</td></tr>
<tr><td width="200">PLT</td><td width="200">190</td><td width="200">1987-4-14</td></tr>
<tr><td width="200">WBC</td><td width="200">9</td><td width="200">1987-4-14</td></tr>
<tr><td width="200">eGFR</td><td width="200">41</td><td width="200">1987-10-14</td></tr>
<tr><td width="200">target_HBA1c</td><td width="200">7.0</td><td width="200">1988-3-21</td></tr>
<tr><td width="200">SGPT</td><td width="200">33</td><td width="200">1987-4-14</td></tr>
<tr><td width="200">Obstructive_Pulmonary_Disease</td><td width="200"></td><td width="200">1987-3-22</td></tr>
<tr><td width="200">Myocardial_Infarction</td><td width="200"></td><td width="200">1987-3-22</td></tr>
<tr><td width="200">Osteoporosis</td><td width="200"></td><td width="200">1987-4-3</td></tr>
<tr><td width="200">Hypertension</td><td width="200"></td><td width="200">1987-12-1</td></tr>
<tr><td width="200">Sex</td><td width="200">Female</td><td width="200"></td></tr>
<tr><td width="200">edema</td><td width="200"></td><td width="200">1988-1-13</td></tr>
<tr><td width="200">Race</td><td width="200">White_Non-Hispanic</td><td width="200"></td></tr>
<tr><td width="200">DM-Type2</td><td width="200"></td><td width="200">1988-3-21</td></tr>
<tr><td width="200">Hepatitis_C_Status</td><td width="200">Negative</td><td width="200">1985-7-1</td></tr>
<tr><td width="200">Coronary_Artery_Disease</td><td width="200"></td><td width="200">1987-3-24</td></tr>
<tr><td width="200">Hepatitis_B_Surface_Antigen</td><td width="200">Negative</td><td width="200">1985-7-1</td></tr>
</table>
<p><b>Medications:</b> triamterene(37.5) aspirin(325.0) simvastatin(20.0) lisinopril(40.0) nitrate(60.0) hydrochlorothiazide(0.0) glimepiride(8.0) furosemide(40.0) Insulin(1.0) 
<p><b>Problems:</b> <table>
<tr><td width="200"><b>Problem Class</b></td><td width="200"><b>First/Last Dates Reported</b></td><td width="200"></td></tr>
<tr><td width="200">CRI</td>
<td width="200"></td>
<td width="200"> Renal Insufficiency[Creatinine(1.3/1987-10-14) && Sex(Female) && Creatinine(1.3/1987-10-14)]()</td></tr>
<tr><td width="200">Target_Organ_Damage_Clinical_Cardiovascular_Disease</td>
<td width="200"></td>
<td width="200"> TOD/CCD[presence of myocardial infarction]()</td></tr>
<tr><td width="200">Dyslipidemia Lab criteria</td>
<td width="200"></td>
<td width="200"> Dyslipidemia Lab criteria[HDL_Cholesterol(34.0/1987-3-21)]()</td></tr>
<tr><td width="200">Presence of K sparing diuretics</td>
<td width="200"></td>
<td width="200"> K sparing diuretics[presence of K sparing diuretics]()</td></tr>
<tr><td width="200">Diabetes WITHOUT proteinuria/renal manifestations</td>
<td width="200"></td>
<td width="200"> Diabetes[presence of diabetes mellitus && Absence of diabetic with renal manifestations && Absence of diabetic nephropathy && Absence of diabetic nephrosis && Proteinuria equals trace or above && Absence of ARB]()</td></tr>
<tr><td width="200">DM (2ary prev)  BP controlled</td>
<td width="200"></td>
<td width="200"> Diabetes (Secondary Prevention)[Treatment_Diastolic_BP(60/null) && Treatment_Systolic_BP(116/null) && presence of diabetes mellitus]()</td></tr>
<tr><td width="200">MI (secondary prevention) BP controlled</td>
<td width="200"></td>
<td width="200"> Myocardial Infarction (Secondary Prevention)[Treatment_Diastolic_BP(60/null) && Treatment_Systolic_BP(116/null) && presence of myocardial infarction]()</td></tr>
<tr><td width="200">Major Cardiovascular Risk Factor</td>
<td width="200"></td>
<td width="200"> Major Cardiovascular Risk Factor[Sex(Female) && Age(88.0/1970-1-1)]()</td></tr>
<tr><td width="200">Dyslipidemia Lab or ICD9</td>
<td width="200"></td>
<td width="200"> Dyslipidemia Lab or ICD9[presence of dyslipidemia lab criteria]()</td></tr>
<tr><td width="200">CKD by eGFR</td>
<td width="200"></td>
<td width="200"> CKD by eGFR[eGFR(41.0/1987-10-14)]()</td></tr>
<tr><td width="200">CKD by eGFR or ICD9 codes</td>
<td width="200"></td>
<td width="200"> CKD[eGFR(41.0/1987-10-14)]()</td></tr>
<tr><td width="200">On meds & Presence of strong contraindication to HCTZ or using bad drug partner</td>
<td width="200"></td>
<td width="200"> Hypertension[taking furosemide && Antihypertensive_Agents]()</td></tr>
<tr><td width="200">Active prescription for thiazide</td>
<td width="200"></td>
<td width="200"> active prescription for thiazide[presence of thiazide diuretics]()</td></tr>
<tr><td width="200">active prescription for furosemide</td>
<td width="200"></td>
<td width="200"> active prescription for furosemide[taking furosemide]()</td></tr>
<tr><td width="200">Age > 65</td>
<td width="200"></td>
<td width="200"> age > 65 years[Age(88.0/1970-1-1)]()</td></tr>
<tr><td width="200">on >= 1 med</td>
<td width="200"></td>
<td width="200"> Combination therapy for HTN[Antihypertensive_Agents]()</td></tr>
<tr><td width="200">taking >= 2 anti hypertensive meds</td>
<td width="200"></td>
<td width="200"> Combination therapy for HTN[Antihypertensive_Agents]()</td></tr>
<tr><td width="200">On 1 drug and there exists contraindicated drug or a compelling drug not given</td>
<td width="200"></td>
<td width="200"> On 1 drug and there exists contraindicated drug or a compelling drug not given[there exists a compellingly indicated drug that is not already given]()</td></tr>
<tr><td width="200">Hypertension with MI and K>=3.5</td>
<td width="200"></td>
<td width="200"> Hypertension with MI and K>=3.5[Potassium(5.2/1987-10-14) && presence of MI]()</td></tr>
<tr><td width="200">Osteoporosis</td>
<td width="200">1987-04-03</td>
<td width="200"> Osteoporosis()</td></tr>
<tr><td width="200">CCS-7.2</td>
<td width="200">1987-03-22</td>
<td width="200"> Myocardial_Infarction()</td></tr>
<tr> <td width="200"></td>
<td width="200">1987-03-24</td>
<td width="200"> Coronary_Artery_Disease()</td></tr>
<tr><td width="200">Hypertension_Inclusive</td>
<td width="200">1987-12-01</td>
<td width="200"> Hypertension()</td></tr>
<tr> <td width="200"></td>
<td width="200"></td>
<td width="200"> Hypertension with MI and K>=3.5[Potassium(5.2/1987-10-14) && presence of MI]()</td></tr>
<tr><td width="200">Endocrine_Diseases</td>
<td width="200">1988-03-21</td>
<td width="200"> DM-Type2()</td></tr>
<tr><td width="200">Hypertension_Defined</td>
<td width="200"></td>
<td width="200"> Hypertension with MI and K>=3.5[Potassium(5.2/1987-10-14) && presence of MI]()</td></tr>
<tr><td width="200">Respiratory_Diseases</td>
<td width="200">1987-03-22</td>
<td width="200"> Obstructive_Pulmonary_Disease()</td></tr>
<tr><td width="200"> <b>Others</b></td>
<td width="200">1985-07-01</td>
<td width="200"> Hepatitis_C_Status()
<tr> <td width="200"></td>
<td width="200">1985-07-01</td>
<td width="200"> Hepatitis_B_Surface_Antigen()
<tr> <td width="200"></td>
<td width="200">1988-01-13</td>
<td width="200"> edema()
<tr> <td width="200"></td>
<td width="200"></td>
<td width="200"> Race()
<tr> <td width="200"></td>
<td width="200"></td>
<td width="200"> Sex()
</table><p>
<p><b>Allergies and Adverse Reactions:</b> <ul>
<li>Substance: sulfonamides Reaction: 
<li>Substance: sulfonamides Reaction: 
 </ul>
</patient>
<h1 align="center">VA/JNC-VII Hypertension Guideline</h1>
<b>Patient classification:</b> <ul>
<li>VA/JNC-VII Hypertension Guideline: true[because <i> Eligibility criteria </i> evaluate to <b>true</b><i>(presence of diagnosis of hypertension && absence of renovascular disease && no diagnosis of pregnancy && Absense of Secondary Hypertension && absence of spinal cord injury && absence of narcolepsy && Not taking cyclosporine && Not taking spironolactone && Not taking minoxidil && absence of renovascular disease && absence of IHSS && Absence of Ascites && Not off guideline && not taking tacrolimus && absence of transplant recipient && Absence of a dialysis procedure code)</i>]
<li>Risk Group C (presence of TOD/CCD or DM): [because <i> presence of TOD/CCD or DM </i> evaluate to <b>true</b><i>(presence of DM)</i>]
</ul>
<b>Scenario choice:</b> on two or three anti-hypertensive drugs
<p>
<b>Goal:</b> SBP < 140 and DBP < 80(presence of diabetes mellitus)
<p><b>Reached goal?</b> achieved(Treatment_Diastolic_BP(60/null) && Treatment_Systolic_BP(116/null))
<p><b>Messages by Types</b>
<ul>
<li><b>Recommendation</b>
<ul>
<li>It is true that 7.3 inches of rain fell yesterday, and the patient is taking the following drugs: nitrate, lisinopril, furosemide, hydrochlorothiazide, Insulin, triamterene
<li>The clinical information from this system is advisory only and is intended to supplement the knowledge of health care professionals regarding the management of hypertension. It is not intended to replace sound clinical judgment or individualized patient care in delivery of healthcare services.
  Although the ATHENA-HTN information is derived from research literature and is subject to review, we cannot guarantee its comprehensiveness or currency. Please note that medical information is dynamic due to ongoing research and clinical experience and is subject to interpretation. There is also the possibility of errors in the programming.  The user of this software assumes sole responsibility for any decisions made or actions taken based the information contained in this software, including but not limited to therapeutic suggestions.  ATHENA-HTN, the Department of Veterans Affairs and Stanford University shall have no liability to any person, or entity with regard to claims, loss, or damage caused, or alleged to be caused, directly or indirectly by the use of this software or the information contained within.  ATHENA-HTN is the property of Stanford's Office Technology Licensing (OTL) and Department of Veterans Affairs.  
By accessing ATHENA-HTN, you agree use ATHENA-HTN only as a reference resource for research. You agree to abstain from using ATHENA-HTN to generate knowledge for treatment.
</ul>
<li><b>Primary_Recommendation</b>
<ul>
<li>Based on most recent BP in the database, BP appears to be adequately controlled; however, ALTERNATIVE DRUGS may be preferred.
</ul>
<li><b>Assumption</b>
<ul>
<li>We did not find a BP in the vitals signs section of the computer.  We are not at present able to use the BP recorded in the text of the progress note, so we are not able to determine whether the BP control is adequate or inadequate.  Please enter BP using the top part of the screen.
</ul>
</ul>
<p><b>Action Choices</b>
<ul>
<li><b>on medication: things to check</b><br>
<ul>
<li><b>assumption  check presence of BP <font color=FF0000>preferred</font></b>(rule in criterion<i> diastolic BP or systolic BP absent</i> evaluate to <b> true</b> because <i>absence of diastolic BP</i>)])
We did not find a BP in the vitals signs section of the computer.  We are not at present able to use the BP recorded in the text of the progress note, so we are not able to determine whether the BP control is adequate or inadequate.  Please enter BP using the top part of the screen.
<li><b>adverse event warning <font color=FF0000>preferred</font></b>(rule in criterion<i> presence of current medication with adverse reaction</i> evaluate to <b> true</b> because <i>presence of current medication with adverse reaction</i>)])
<li><b>Furosemide without CHF or RF <font color=FF0000>preferred</font></b>(rule in criterion<i> On Furosemide with No CHF or RF</i> evaluate to <b> true</b> because <i>taking loop diuretic (furosemide ) && absence of heart failure && absence of renal insufficiency</i>)])
Patient is taking furosemide or a loop diuretic and appears to have neither CHF nor renal insufficiency. Hydrochlorothiazide is generally a more efficacious diuretic in the management of hypertension.
<li><b>test parameterized message <font color=FF0000>preferred</font></b>(rule in criterion<i> true</i> evaluate to <b> true</i>)])
It is true that 7.3 inches of rain fell yesterday, and the patient is taking the following drugs: nitrate, lisinopril, furosemide, hydrochlorothiazide, Insulin, triamterene
<li><b>Disclaimer <font color=FF0000>preferred</font></b>(rule in criterion<i> true</i> evaluate to <b> true</i>)])
The clinical information from this system is advisory only and is intended to supplement the knowledge of health care professionals regarding the management of hypertension. It is not intended to replace sound clinical judgment or individualized patient care in delivery of healthcare services.
  Although the ATHENA-HTN information is derived from research literature and is subject to review, we cannot guarantee its comprehensiveness or currency. Please note that medical information is dynamic due to ongoing research and clinical experience and is subject to interpretation. There is also the possibility of errors in the programming.  The user of this software assumes sole responsibility for any decisions made or actions taken based the information contained in this software, including but not limited to therapeutic suggestions.  ATHENA-HTN, the Department of Veterans Affairs and Stanford University shall have no liability to any person, or entity with regard to claims, loss, or damage caused, or alleged to be caused, directly or indirectly by the use of this software or the information contained within.  ATHENA-HTN is the property of Stanford's Office Technology Licensing (OTL) and Department of Veterans Affairs.  
By accessing ATHENA-HTN, you agree use ATHENA-HTN only as a reference resource for research. You agree to abstain from using ATHENA-HTN to generate knowledge for treatment.
</ul>
<li><b>two or three drug-therapy choices</b><br>
<ul>
<li><b>on two or three drugs, consider substituting one <font color=FF0000>preferred</font></b>(strict rule-in condition<i> No constraindicated drug and (BP adequately controlled but compellingly indicated drug not given) </i> evaluate to <b> true</b> because <i>Treatment_Diastolic_BP(60/null) && Treatment_Systolic_BP(116/null) && there exists a compellingly indicated drug that is not already given && there exists a non-betablocker, non-ACE, non-clonidine , non (alpha blocker + BPH)drug to replace && (~B)no current drug contraindicatedthere exists a contraindicated current med</i>)])
Based on most recent BP in the database, BP appears to be adequately controlled; however, ALTERNATIVE DRUGS may be preferred.

</ul>
<li><b>substitution messages</b><br>
<ul>
<li><b>NO ADE recommended drug SUB <font color=FF0000>preferred</font></b>(rule in criterion<i> there exists recommended drug and none has ADE</i> evaluate to <b> true</b> because <i>No recommended drug has adverse event && recommend delete</i>)])
No adverse reactions are listed for the antihypertensive drug(s) we are recommending.  If the patient has had an adverse reaction, please enter it in a progress note entitled "Adverse Reactions/Allergy".
</ul>
</ul>
<b>Considerations for substituting drug: </b><ul><li> Substitution: replace <ul><li>furosemide(Loop_diuretics)<ul><li>Furosemide without CHF or RF(Patient is taking furosemide and appears to have neither CHF nor renal failure. Hydrochlorothiazide is generally the more efficacious diuretic in the management of hypertension.)</ul><li>triamterene(Potassium-Sparing_Diuretics)<ul><li>No comment</ul> with <li>ACE Inhibitor (lisinopril)<ul><li>Already being used<li>Drugs with bad interactions:  Potassium-Sparing_Diuretics(triamterene) <li><font color=FF0000>Compelling indications:  Diabetes_Mellitus(DM-Type2)  DM (2ary prev)  BP controlled(Diabetes (Secondary Prevention)[Treatment_Diastolic_BP(60/null) && Treatment_Systolic_BP(116/null) && presence of diabetes mellitus])  CKD by eGFR or ICD9 codes(CKD[eGFR(41.0/1987-10-14)]) </font><li>Relative contraindications:  Presence of K sparing diuretics(K sparing diuretics[presence of K sparing diuretics]) <li>preference: ruled out</ul><li>Alpha Blocker (terazosin)<ul><li>preference: neutral<li>No comment</ul><li>Cardioselective Beta Blocker (metoprolol)<ul><li>Drugs to partner:  Thiazide_Diuretics(hydrochlorothiazide) <li><font color=FF0000>Compelling indications:  Myocardial_Infarction(Myocardial_Infarction)  MI (secondary prevention) BP controlled(Myocardial Infarction (Secondary Prevention)[Treatment_Diastolic_BP(60/null) && Treatment_Systolic_BP(116/null) && presence of myocardial infarction]) </font><li>Relative indications:  Coronary_Artery_Disease(Coronary_Artery_Disease)  CKD by eGFR or ICD9 codes(CKD[eGFR(41.0/1987-10-14)])  Diabetes_Mellitus(DM-Type2) <li>Relative contraindications:  Obstructive_Pulmonary_Disease(Obstructive_Pulmonary_Disease) <li>Add Beta blocker and DM(Beta blockers may diminish symptoms of and recovery from hypoglycemia and should be used with caution in patients who are prone to hypoglycemia.)<li>add metoprolol, adjust dose other drugs(When adding metoprolol to this patient's therapeutic regime a dose adjustment of other anti-hypertensive drugs may be required.)<li>add beta blocker, obstructive pulmonary disease(Cardiovascular benefits of beta blocker therapy may outweigh the increased risk of bronchospasm in this patient.)<li>betablocker dyslipidemia warning message(Beta blockers may have transient adverse effects on lipids in some patients.  Consider repeating lipid profile after maximal dosage of drug has been reached if appropriate.)<li>disclaimer about procedure reports delete(Diagnoses from EKG reports are not extracted. If patient has an arrythmia that is not shown in patient summary, please update problem list.)<li>MI (BB)  and JNC7 rec aldosterone antag(Beta Adrenergic Receptor Antagonist is compellingly indicated for post MI by JNC7 and 2004 VA Guidelines, JNC7 also has aldosterone antagonists as a compelling indication for MI.)<li>preference: preferred</ul><li>DHP Calcium Channel Blocker (felodipine, nifedipine SA)<ul><li>Relative indications:  Diabetes_Mellitus(DM-Type2) <li>preference: neutral</ul><li>(non-DHP) Calcium Channel Blocker (diltiazem)<ul><li>Relative indications:  CKD by eGFR or ICD9 codes(CKD[eGFR(41.0/1987-10-14)]) <li>preference: neutral</ul></ul></ul></body></html>